| Generic name | Pentostatin |
| Pronunciation | pen-toh-STAT-in |
| Brand name(s), other common name(s) | Nipent® |
| Drug type | Antimetabolite |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Pentostatin is FDA approved as a single-agent treatment for both untreated and alfa-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia (abnormally low white blood count), thrombocytopenia (reduced platelet count), or disease-related symptoms.
Side effects needing medical attention
Fever; chills; bone pain; weakness and fatigue; lack of coordination, especially in walking; skin disorders; unusual decrease or increase in urination; cough; inflammation of the eye; flulike symptoms; confusion; depression; dizziness; drowsiness; nausea and vomiting; decreased appetite; diarrhea; headache.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.